Annovis Bio Inc (ANVS)
5.56
-0.53
(-8.70%)
USD |
NYSE |
Jun 25, 16:00
5.56
0.00 (0.00%)
Pre-Market: 20:00
Annovis Bio Research and Development Expense (TTM): 37.52M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 37.52M |
| December 31, 2023 | 38.79M |
| September 30, 2023 | 36.09M |
| June 30, 2023 | 26.38M |
| March 31, 2023 | 22.15M |
| December 31, 2022 | 16.52M |
| September 30, 2022 | 13.19M |
| June 30, 2022 | 10.45M |
| March 31, 2022 | 8.239M |
| December 31, 2021 | 8.479M |
| September 30, 2021 | 7.007M |
| Date | Value |
|---|---|
| June 30, 2021 | 6.345M |
| March 31, 2021 | 5.377M |
| December 31, 2020 | 3.054M |
| September 30, 2020 | 2.404M |
| June 30, 2020 | 1.687M |
| March 31, 2020 | 0.8367M |
| December 31, 2019 | 0.7763M |
| September 30, 2019 | 0.0274M |
| June 30, 2019 | 0.0386M |
| March 31, 2019 | 0.0598M |
| December 31, 2018 | 0.1116M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
0.0274M
Minimum
Sep 2019
38.79M
Maximum
Dec 2023
12.27M
Average
7.623M
Median
Research and Development Expense (TTM) Benchmarks
| ANI Pharmaceuticals Inc | 38.87M |
| Ligand Pharmaceuticals Inc | 23.84M |
| FibroGen Inc | 246.77M |
| SINTX Technologies Inc | 8.516M |
| Nortech Systems Inc | 1.241M |